The pharmacology and clinical use of caspofungin

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 2, 2007, Pages 263-274

  Hope, William W ^a   Shoham, Shmuel ^a,b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Aspergillus; Candida; Caspofungin; Echinocandin; Glucan; Pharmacodynamics; Pharmacokinetics

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BETA 1,3 GLUCAN; BETA 1,6 GLUCAN; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; GLUCAN SYNTHASE; ITRACONAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; CYCLOPEPTIDE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CARBOHYDRATE SYNTHESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FUNGAL GENETICS; HUMAN; INVASIVE CANDIDIASIS; KIDNEY DISEASE; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NONHUMAN; OROPHARYNX CANDIDIASIS; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; SALVAGE THERAPY; SINGLE DRUG DOSE; THERAPY RESISTANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; CANDIDIASIS; CHEMICAL STRUCTURE; CHEMISTRY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; REVIEW; TISSUE DISTRIBUTION;

ASPERGILLUS; CANDIDA;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 34547202083     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.2.263     Document Type: Article

References (84)

1. IBRAHIM AS, BOWMAN JC, AVANESSIAN V et al.: Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. (2005) 49:721-727.
2. SPELLBERG B, FU Y, EDWARDS JE Jr, IBRAHIM AS: Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. (2005) 49:830-832.
3. SPELLBERG B, SCHWARTZ J, FU Y et al.: Comparison of antifungal treatments for murine fusariosis. J. Antimicrob. Chemother. (2006) 58:973-979.
4. FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. (2000) 182:1791-1795.
5. THOMPSON JR, DOUGLAS CM, LI W et al.: A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. (1999) 181:444-453.
6. MALIGIE MA, SELITRENNIKOFF CP: Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother. (2005) 49:2851-2856.
7. REINOSO-MARTIN C, SCHULLER C, SCHUETZER-MUEHLBAUER M, KUCHLER K: The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot. Cell (2003) 2:1200-1210.
8. QADOTA H, PYTHON CP, INOUE SB et al.: Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase. Science (1996) 272:279-281.
9. DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. (1997) 41:2471-2479.
10. PARK S, KELLY R, KAHN JN et al.: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. (2005) 49:3264-3273.
11. STEVENS DA, ICHINOMIYA M, KOSHI Y, HORIUCHI H: Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. (2006) 50:3160-3161.
12. DOUGLAS CM, FOOR F, MARRINAN JA et al.: The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc. Natl. Acad. Sci. USA (1994) 91:12907-12911.
13. PADERU P, PARK S, PERLIN DS: Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob. Agents Chemother. (2004) 48:3845-3849.
14. DOUGLAS CM: Fungal beta(1,3)-D-glucan synthesis. Med. Mycol. (2001) 39(Suppl. 1):55-66.
15. MAZUR P, MORIN N, BAGINSKY W et al.: Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol. Cell Biol. (1995) 15:5671-5681.
16. MAZUR P, BAGINSKY W: In vitro activity of 1,3-beta-D-glucan synthase requires the GTP-binding protein Rho1. J. Biol. Chem. (1996) 271:14604-14609.
17. BUSSEY H: Cell shape determination: a pivotal role for Rho. Science (1996) 272:224-225.
18. KONDOH O, TACHIBANA Y, OHYA Y, ARISAWA M, WATANABE T: Cloning of the RHO1 gene from Candida albicans and its regulation of beta-1,3-glucan synthesis. J. Bacteriol. (1997) 179:7734-7741.
19. BEAUVAIS A, BRUNEAU JM, MOL PC, BUITRAGO MJ, LEGRAND R, LATGE JP: Glucan synthase complex of Aspergillus fumigatus. J. Bacteriol. (2001) 183:2273-2279.
20. HERNANDEZ S, LOPEZ-RIBOT JL, NAJVAR LK, MCCARTHY DI, BOCANEGRA R, GRAYBILL JR: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. (2004) 48:1382-1383.
21. BALASHOV SV, PARK S, PERLIN DS: Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. (2006) 50:2058-2063.
22. KATIYAR S, PFALLER M, EDLIND T: Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. (2006) 50:2892-2894.
23. LAVERDIERE M, LALONDE RG, BARIL JG, SHEPPARD DC, PARK S, PERLIN DS: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. (2006) 57:705-708.
24. MILLER CD, LOMAESTRO BW, PARK S, PERLIN DS: Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy (2006) 26:877-880.
25. GARDINER RE, SOUTEROPOULOS P, PARK S, PERLIN DS: Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. (2005) 43(Suppl. 1):S299-S305.
26. BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2326-2332.
27. STONE JA, HOLLAND SD, WICKERSHAM PJ et al.: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. (2002) 46:739-745.
28. GROLL AH, GULLICK BM, PETRAITIENE R et al.: Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob. Agents Chemother. (2001) 45:596-600.
29. LOUIE A, DEZIEL M, LIU W, DRUSANO MF, GUMBO T, DRUSANO GL: Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. (2005) 49:5058-5068.
30. HAJDU R, THOMPSON R, SUNDELOF JG et al.: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2339-2344.
31. GROLL AH, WALSH TJ: Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs (2001) 10:1545-1558.
32. WIEDERHOLD NP, KONTOYIANNIS DP, CHI J, PRINCE RA, TAM VH, LEWIS RE: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. (2004) 190:1464-1471.
33. CLEARY JD, SCHWARTZ M, ROGERS PD, DE MESTRAL J, CHAPMAN SW: Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy (2003) 23:966-973.
34. STONE JA, XU X, WINCHELL GA et al.: Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob. Agents Chemother. (2004) 48:815-823.
35. SANDHU P, XU X, BONDISKEY PJ et al.: Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob. Agents Chemother. (2004) 48:1272-1280.
36. SANDHU P, LEE W, XU X et al.: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. (2005) 33:676-682.
37. BALANI SK, XU X, ARISON BH et al.: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. (2000) 28:1274-1278.
38. GROLL AH, ATTARBASCHI A, SCHUSTER FR et al.: Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J. Antimicrob. Chemother. (2006) 57:527-535.
39. WALSH TJ, ADAMSON PC, SEIBEL NL et al.: Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. (2005) 49:4536-4545.
40. ODIO CM, ARAYA R, PINTO LE et al.: Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. (2004) 23:1093-1097.
41. STONE JA, MIGOYA EM, HICKEY L et al.: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. (2004) 48:4306-4314.
42. ODDS FC, MOTYL M, ANDRADE R et al.: Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. (2004) 42:3475-3482.
43. KARTSONIS N, KILLAR J, MIXSON L et al.: Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother. (2005) 49:3616-3623.
44. ERNST EJ, KLEPSER ME, ERNST ME, MESSER SA, PFALLER MA: In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. (1999) 33:75-80.
45. BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46:3001-3012.
46. PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. (2002) 46:12-23.
47. ABRUZZO GK, GILL CJ, FLATTERY AM et al.: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. (2000) 44:2310-2318.
48. BOWMAN JC, ABRUZZO GK, ANDERSON JW et al.: Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. (2001) 45:3474-3481.
49. IMAI J, SINGH G, FERNANDEZ B, CLEMONS KV, STEVENS DA: Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J. Antimicrob. Chemother. (2005) 56:166-171.
50. SINGH G, IMAI J, CLEMONS KV, STEVENS DA: Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob. Agents Chemother. (2005) 49:1369-1376.
51. CLEMONS KV, ESPIRITU M, PARMAR R, STEVENS DA: Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. (2005) 49:4867-4875.
52. STEVENS DA, ESPIRITU M, PARMAR R: Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. (2004) 48:3407-3411.
53. CLEMONS KV, ESPIRITU M, PARMAR R, STEVENS DA: Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. (2006) 50:1293-1297.
54. STEVENS DA, WHITE TC, PERLIN DS, SELITRENNIKOFF CP: Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. (2005) 51:173-178.
55. WIEDERHOLD NP, KONTOYIANNIS DP, PRINCE RA, LEWIS RE: Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother. (2005) 49:5146-5148.
56. BACHMANN SP, VANDEWALLE K, RAMAGE G et al.: In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. (2002) 46:3591-3596.
57. SHUFORD JA, ROUSE MS, PIPER KE, STECKELBERG JM, PATEL R: Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J. Infect. Dis. (2006) 194:710-713.
58. RAMAGE G, VANDEWALLE K, BACHMANN SP, WICKES BL, LOPEZ-RIBOT JL: In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. (2002) 46:3634-3636.
59. ERNST EJ, KLEPSER ME, PFALLER MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44:1108-1111.
60. PETRAITIS V, PETRAITIENE R, SARAFANDI AA et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. (2003) 187:1834-1843.
61. MACCALLUM DM, WHYTE JA, ODDS FC: Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. (2005) 49:3697-3701.
62. KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF: Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. (2002) 46:2564-2568.
63. DEL POETA M, CRUZ MC, CARDENAS ME, PERFECT JR, HEITMAN J: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK-506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44:739-746.
64. STEINBACH WJ, SCHELL WA, BLANKENSHIP JR, ONYEWU C, HEITMAN J, PERFECT JR: In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob. Agents Chemother. (2004) 48:1664-1669.
65. WALSH TJ, TEPPLER H, DONOWITZ GR et al.: Caspofungin versus liposomal ansphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. (2004) 351:1391-1402.
66. VILLANUEVA A, ARATHOON EG, GOTUZZO E, BERMAN RS, DINUBILE MJ, SABLE CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. (2001) 33:1529-1535.
67. ARATHOON EG, GOTUZZO E, NORIEGA LM, BERMAN RS, DINUBILE MJ, SABLE CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. (2002) 46:451-457.
68. VILLANUEVA A, GOTUZZO E, ARATHOON EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113:294-299.
69. KARTSONIS N, DINUBILE MJ, BARTIZAL K, HICKS PS, RYAN D, SABLE CA: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune Defic. Syndr. (2002) 31:183-187.
70. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
71. JIMENEZ-EXPOSITO MJ, TORRES G, BARALDES A et al.: Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin. Infect. Dis. (2004) 39:e70-e73.
72. MROWCZYNSKI W, WOJTALIK M: Caspofungin for Candida endocarditis. Pediatr. Infect. Dis. J. (2004) 23:376.
73. RAJENDRAM R, ALP NJ, MITCHELL AR, BOWLER IC, FORFAR JC: Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin. Infect. Dis. (2005) 40:e72-e74.
74. LYE DC, HUGHES A. O'BRIEN D, ATHAN E: Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:753-755.
75. KONTNY U, WALSH TJ, ROSSLER J, UHL M, NIEMEYER CM: Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr. Blood Cancer (2006). Epub ahead of print.
76. BREIT SM, HARIPRASAD SM, MIELER WF, SHAH GK, MILLS MD, GRAND MG: Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am. J. Ophthalmol. (2005) 139:135-140.
77. SARRIA JC, BRADLEY JC, HABASH R, MITCHELL KT, KIMBROUGH RC, VIDAL AM: Candida glabrata endophthalmitis treated successfully with caspofungin. Clin. Infect. Dis. (2005) 40:e46-e48.
78. LIU KH, WU CJ, CHOU CH et al.: Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J. Clin. Microbiol. (2004) 42:5950-5953.
79. GAUTHIER GM, NORK TM, PRINCE R, ANDES D: Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin. Infect. Dis. (2005) 41:e27-e28.
80. PELLETIER R, ALARIE I, LAGACE R, WALSH TJ: Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. (2005) 43:559-564.
81. MAERTENS J, RAAD I, PETRIKKOS G et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. (2004) 39:1563-1571.
82. MARR KA, BOECKH M, CARTER RA, KIM HW, COREY L: Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. (2004) 39:797-802.
83. SINGH N, LIMAYE AP, FORREST G et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 81:320-326.
84. DENNING DW: Echinocandin antifungal drugs. Lancet (2003) 362:1142-1151.